Acrivon Therapeutics: Promising Clinical Data and Strategic Progress Justify Buy Rating
In a report released yesterday, Etzer Darout from BMO Capital reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research ...
Strong Growth Outlook for Acrivon Therapeutics, Inc. Backed by Promising Pipeline and Strategic Advancements
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) yesterday and set a ...